MINT Trial findings published in Circulation

The concern for harm with a restrictive transfusion strategy in patients with acute myocardial infarction (MI) and anemia may be more apparent in patients with type 1 than type 2 MI.

The Myocardial Ischemia and Transfusion (MINT) randomized trial indicated that a liberal red blood cell transfusion strategy may be beneficial as compared to a restrictive strategy for patients with acute myocardial infarction and anemia.   A secondary analysis of the MINT trial, published in Circulation and co-authored by EDC Data Scientist Brandon Herbert and University of Pittsburgh investigator and Epidemiology Data Center faculty Marnie Bertolet, investigated whether or not the impact of the transfusion strategy on 30-day death or recurrent myocardial infarction varied whether the participant had a Type 1 or Type 2 index MI. The authors found that patients with Type 1 MI had a higher risk of the outcome in the restrictive group compared to the liberal group.  This was not true for patients with Type 2 MI.  However, the type of index MI did not modify transfusion strategy treatment effect. Previous data that established that the restrictive transfusion strategy is safe for many patient populations should not be applied to patients with acute MI and anemia, particularly in type 1 MI.

https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.071208
DeFilippis AP, Abbott JD, Herbert BM, Bertolet MH, Chaitman BR, White HD, Goldsweig AM, Polonsky TS, Gupta R, Alsweiler C, Silvain J, de Barros E Silva PGM, Hillis GS, Daneault B, Tessalee M, Menegus MA, Rao SV, Lopes RD, Hébert PC, Alexander JH, Brooks MM, Carson JL, Goodman SG; MINT Investigators. Circulation. 2024 Dec 3;150(23):1826-1836. doi: 10.1161/CIRCULATIONAHA.124.071208. Epub 2024 Aug 29.

PMID: 39206549